This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Reata (RETA) Q2 Earnings Top, Omaveloxolone Setback Hurts
by Zacks Equity Research
Reata (RETA) gets FDA recommendation to initiate a second study on omaveloxolone for additional data.
Esperion (ESPR) Q2 Earnings Top, Drug Sales Hurt by Coronavirus
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed second-quarter results as it beats estimates for earnings and misses for sales.
AVEO Pharmaceuticals' (AVEO) Q2 Earnings Surpass Estimates
by Zacks Equity Research
AVEO (AVEO) reports a narrower-than-expected loss but misses sales estimates in the second quarter of 2020.
Biohaven (BHVN) Q2 Earnings Beat on Strong Nurtec Uptake
by Zacks Equity Research
Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, demonstrates strong launch uptake.
Editas' (EDIT) Earnings Beat in Q2, Revenues Improve Y/Y
by Zacks Equity Research
Editas' (EDIT) both bottom and the top line better estimates for the second quarter of 2020.
Iovance (IOVA) Q2 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Iovance's (IOVA) second-quarter bottom line beats estimates. The company is progressing well with its lead pipeline candidates.
Amicus' (FOLD) Q2 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Amicus (FOLD) posts a narrower-than-expected loss, while sales beat estimates in the second quarter of 2020.
Horizon Therapeutics (HZNP) Looks Good: Stock Adds 5.3% in Session
by Zacks Equity Research
Horizon Therapeutics (HZNP) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Puma's (PBYI) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
Puma Biotech's (PBYI) bottom and the top line better estimates for the second quarter of 2020.
Clovis (CLVS) Q2 Earnings Lag, Revenues Show Coronavirus Impact
by Zacks Equity Research
Clovis (CLVS) reports dismal second-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares down.
Aerie (AERI) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Aerie (AERI) posts a wider-than-expected loss and sales miss estimates in the second quarter of 2020.
AMAG Pharmaceuticals' (AMAG) Q2 Loss Narrower Than Expected
by Zacks Equity Research
AMAG (AMAG) posts a narrower-than-expected loss and revenues miss estimates in the second quarter of 2020.
Zacks.com featured highlights include: Boise Cascade, Century Communities, Emergent BioSolutions and Deckers Outdoor
by Zacks Equity Research
Zacks.com featured highlights include: Boise Cascade, Century Communities, Emergent BioSolutions and Deckers Outdoor
Top Ranked Momentum Stocks to Buy for August 7th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 7th
ACADIA (ACAD) Q2 Earnings Surpass, Nuplazid Drives Sales
by Zacks Equity Research
ACADIA (ACAD) beats on earnings and revenues for the second quarter. The company lifts the lower end of its net sales view for Nuplazid, driving the stock in pre-market trading.
Emergent Biosolutions (EBS) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Emergent Biosolutions (EBS) could produce exceptional returns because of its solid growth attributes.
Horizon (HZNP) Q2 Earnings Down Y/Y, Tepezza Drives Sales
by Zacks Equity Research
Horizon Therapeutics' (HZNP) earnings decline year over year and sales beat estimates in the second quarter of 2020.
Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) beats both earnings and sales estimates in the second quarter of 2020.
Allogene's (ALLO) Q2 Loss Widens Y/Y, Pipeline Progresses
by Zacks Equity Research
Allogene (ALLO) reports no revenues for the second quarter of 2020.
Sarepta (SRPT) Q2 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Sarepta (SRPT) Q2 revenues increase year over year.
Emergent BioSolutions' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Emergent BioSolutions.
Arena Pharmaceuticals (ARNA) Q2 Loss Narrower Than Expected
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) beats bottom-line estimates for the second quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.
BioDelivery (BDSI) Q2 Earnings Miss, Revenues Beat, Stock Up
by Zacks Equity Research
BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues. Stock up.
4 Solid Momentum Picks Screened on Driehaus Strategy
by Nitish Marwah
Investors who have the tendency to take a high level of risk can choose momentum stocks.